To assess the impacts of Elidel ® (pimecrolimus) cream 1% usage, in routine Belgian clinical practice in patients with mild to moderate atopic dermatitis, in terms of: pimecrolimus drug consumption; use of topical corticosteroids; quality of life; and safety. METHODS: An open-label, single arm, observational, multicenter study with one year follow-up to cover the seasonality of atopic dermatitis. Yearly pimecrolimus drug consumption was estimated based on the number and quantity of delivered prescriptions and on the number of unused or partially used tubes left at the end of the study. Topical corticosteroid use was assessed by a steroid usage questionnaire and the delivered topical corticosteroid prescriptions. Quality of life was gauged using validated disease specific instruments, i.e. the Parents'Index Quality of Life-Atopic Dermatitis (PIQoL-AD) or the Quality of Life Index-Atopic Dermatitis (QoLIAD), depending on patient's age. All adverse events were recorded. RESULTS: A total of 416 patients were enrolled from 49 study centers geographically spread over Belgium. For patients who completed this 12 months study, the mean (SD) amount of prescribed pimecrolimus cream 1% per patient was 120.8 (117.0) gram per year, with an estimated consumption of 104.4 (117.6) gram per year. Topical corticosteroids were used before the study in 81.7% of the population. At the end of study 83.3% of them stated that they were using less topical corticosteroids when pimecrolimus is part of their treatment regimen. Mean (SD) improvements versus baseline in PIQoL-AD and QoLIAD scores were 34.5% (84.3%) and 31.2% (70.8%), respectively. Median (IQR) improvements were 50.0% (12.5%-85.7%) and 46.4% (0.0%-85.0%), respectively. Pimecrolimus also showed good tolerability profile. CONCLUSIONS: This observational study showed favorable pimecrolimus profile in routine practice reflected by relatively small amount of drug used, corticosteroid sparing effect, improvement in quality of life, and good tolerability. Generic Quality of Life (QoL) instruments are useful to compare different populations. However these instruments could be criticized for having some drawbacks, and disease-specific instruments could be preferred to measure those aspects of wellbeing influenced by a specific disease and to effectively measure health changes over the time. OBJECTIVE: We tested convergent validity and sensitivity to change over time of a generic and diseasespecific pediatric questionnaires to evaluate wellbeing in children with Atopic Dermatitis (AD), a very frequent, chronic and disabling disease. METHODS: Data from the Costi-&-Outcomesin-Dermatite-Atopica (CODA) naturalistic, prospective Cost-OfIllness study, involving moderate and severe AD patients, were used. Patients aged 5-16 y.o. and/or their caregivers completed twice (at flare-up and after 2 months) the KINDL (childrenreported version: KINDL-C, parent-reported version: KINDL-P; scores = 0-100, higher score = higher QoL) and CDLQI (Children's-Dermatology-Life-Quality-Index, with scores = 0-30, higher score = lower QoL). Patients' clinical status was evaluated with the SCORAD index (SCORing-Atopic-Dermatitis, possible score = 0-100, higher score = higher severity). We tested convergent validity by investigating correlations between QoL instruments; sensitivity to change over time was tested with paired students' t tests, Standardized Response Mean (SRM), Effect Size (EF). RESULTS: Pediatric patients were 66, 43.9% male, median age = 8.8 y.o., median SCORAD at enrolment = 41.5 (3.0-85.0). CDLQI significantly correlated with KINDL-P (Spearman's r = −0.44 p = 0.001) and KINDL-C (r = −0.36 p = 0.008), KINDL-P sensitively correlated with KINDL-C (r = 0.67 p < 0.0001). At follow-up clinical severity significantly decreased (Student's paired t test, p < 0.0001). Patients reported significant lower scores of CDLQI (Student's paired t test, p < 0.05), while no statistical change was found with KINDL-P and KINDL-C. SRM and ES were moderate for CDLQI (SRM = 0.44, ES = 0.41) and low for KINDL-C (SRM = 0.26, ES = 0.26) and KINDL-P (SRM = 0.12, ES = 0.11). CONCLUSION: KINDL significantly correlated with CDLQI, anyway sensitivity to change results were moderate to low. Understanding these properties in QoL questionnaires is necessary to allow their appropriate use and interpretation of QoL data. Generic instruments such as EQ-5D are useful to compare quality of life (QoL) of different populations and to include QoL information in health-economic research. However these instruments could be criticized for having some drawbacks, and disease-specific instruments could be more capable to measure those aspects of wellbeing influenced by a specific disease and could be more sensitive to measure health changes over the time. OBJECTIVE: We tested convergent validity and sensitivity to change over time of EQ-5D and the Dermatology-Life-QualityIndex (DLQI, possible scores = 0-30, higher score = lower QoL) in Atopic Dermatitis (AD), a very frequent, chronic, sensitively disabling disease. METHODS: Data from the Costi-&-Outcomes-in-Dermatite-Atopica (CODA) naturalistic, prospective, Cost-Of-Illness study, involving moderate and severe AD patients, were used. Socio-demographic, clinical severity (with SCORAD, SCORing-Atopic-Dermatitis index, possible score = 0-100, higher score = higher severity), economic and QoL data were collected. Patients from 16 y.o. self-completed twice (at flare-up and after 2 months) EQ-5D and DLQI. We tested correlation of EQ-5D indexes with DLQI and sensitivity to change over time of these indexes with paired Students' t tests, Standardized Response Mean (SRM), Effect Size (EF). RESULTS: Patients were 98, 48% male, median age = 30.5 y.o. . At enrolment median SCORAD = 53.0 (18.4-90.0), median EQ-VAS = 65.0 (0.0-95.0), median utility score from EQ-profile =
PSK7 CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF GENERIC AND DISEASE-SPECIFIC INSTRUMENTS USED IN CHILDREN WITH ATOPIC DERMATITIS
Generic Quality of Life (QoL) instruments are useful to compare different populations. However these instruments could be criticized for having some drawbacks, and disease-specific instruments could be preferred to measure those aspects of wellbeing influenced by a specific disease and to effectively measure health changes over the time. OBJECTIVE: We tested convergent validity and sensitivity to change over time of a generic and diseasespecific pediatric questionnaires to evaluate wellbeing in children with Atopic Dermatitis (AD), a very frequent, chronic and disabling disease. METHODS: Data from the Costi-&-Outcomesin-Dermatite-Atopica (CODA) naturalistic, prospective Cost-OfIllness study, involving moderate and severe AD patients, were used. Patients aged 5-16 y.o. and/or their caregivers completed twice (at flare-up and after 2 months) the KINDL (childrenreported version: KINDL-C, parent-reported version: KINDL-P; scores = 0-100, higher score = higher QoL) and CDLQI (Children's-Dermatology-Life-Quality-Index, with scores = 0-30, higher score = lower QoL). Patients' clinical status was evaluated with the SCORAD index (SCORing-Atopic-Dermatitis, possible score = 0-100, higher score = higher severity). We tested convergent validity by investigating correlations between QoL instruments; sensitivity to change over time was tested with paired students' t tests, Standardized Response Mean (SRM), Effect Size (EF). RESULTS: Pediatric patients were 66, 43.9% male, median age = 8.8 y.o., median SCORAD at enrolment = 41.5 (3.0-85.0). CDLQI significantly correlated with KINDL-P (Spearman's r = −0.44 p = 0.001) and KINDL-C (r = −0.36 p = 0.008), KINDL-P sensitively correlated with KINDL-C (r = 0.67 p < 0.0001). At follow-up clinical severity significantly decreased (Student's paired t test, p < 0.0001). Patients reported significant lower scores of CDLQI (Student's paired t test, p < 0.05), while no statistical change was found with KINDL-P and KINDL-C. SRM and ES were moderate for CDLQI (SRM = 0.44, ES = 0.41) and low for KINDL-C (SRM = 0.26, ES = 0.26) and KINDL-P (SRM = 0.12, ES = 0.11). CONCLUSION: KINDL significantly correlated with CDLQI, anyway sensitivity to change results were moderate to low. Understanding these properties in QoL questionnaires is necessary to allow their appropriate use and interpretation of QoL data. Generic instruments such as EQ-5D are useful to compare quality of life (QoL) of different populations and to include QoL information in health-economic research. However these instruments could be criticized for having some drawbacks, and disease-specific instruments could be more capable to measure those aspects of wellbeing influenced by a specific disease and could be more sensitive to measure health changes over the time. OBJECTIVE: We tested convergent validity and sensitivity to change over time of EQ-5D and the Dermatology-Life-QualityIndex (DLQI, possible scores = 0-30, higher score = lower QoL) in Atopic Dermatitis (AD), a very frequent, chronic, sensitively disabling disease. METHODS: Data from the Costi-&-Outcomes-in-Dermatite-Atopica (CODA) naturalistic, prospective, Cost-Of-Illness study, involving moderate and severe AD patients, were used. Socio-demographic, clinical severity (with SCORAD, SCORing-Atopic-Dermatitis index, possible score = 0-100, higher score = higher severity), economic and QoL data were collected. Patients from 16 y.o. self-completed twice (at flare-up and after 2 months) EQ-5D and DLQI. We tested correlation of EQ-5D indexes with DLQI and sensitivity to change over time of these indexes with paired Students' t tests, Standardized Response Mean (SRM), Effect Size (EF). RESULTS: Patients were 98, 48% male, median age = 30.5 y.o. . At enrolment median SCORAD = 53.0 (18.4-90.0), median EQ-VAS = 65.0 (0.0-95.0), median utility score from EQ-profile = 0.69 (−0.24 to 1.00), median DLQI = 10.0 (0.0-30.0). EQ-VAS and utilities significantly correlated with DLQI (Spearman's coefficient >−0.500, p < 0.0001 in every case). At follow-up SCORAD significantly decreased and patients reported significant higher levels of QoL with every score (Student's paired t test, p < 0.0001 in every index). SRM (EQ-VAS = 0.85, utility = 0.70, DLQI = 0.89) and ES (EQ-VAS = 0.90, utility = 0.76, DLQI = 0.81) were significant. CONCLUSION: EQ-5D and DLQI are good to measure QoL related to AD and to evaluate wellbeing change over time. A routine use of these instruments should be considered in evaluating consequences of AD and its treatment on patients' wellbeing to optimize therapeutic choices. 
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PSK9 QUALITY OF LIFE OF ADULT PATIENTS WITH ATOPIC
METHODS:
It was a naturalistic, multicenter, longitudinal, ambispective (retro-prospective), prevalence-based Cost-OfIllness study enrolling adult and pediatric patients with moderate or severe AD and flare-up. Data was on socio-demographic, clinical severity (with SCORAD, SCORing-Atopic-Dermatitis index, possible score = 0-100, higher score = higher severity), economic (direct and indirect costs), intangible costs in terms of Health-Related-Quality-of-Life (HRQoL), preferences towards pharmacological treatment. Following results pertain to adult patients' HRQoL, evaluated with the disease-specific DLQI (Dermatology-Life-Quality-Index, with scores 0-30, higher score = lower HRQoL) and the generic EQ-5D. RESULTS: A total of 98 valid adult patients (48% male) from 5 Italian dermatological centres were enrolled; 39.8% patients were 18-27 y.o., 30.6% were 28-37 y.o., 29.6% were >38 y.o. At enrollment the median SCORAD was 53.0 (18.4-90.0), the median DLQI was 10.0 (0.0-30.0), the median EQ-VAS (EQ-Visual-Analogue-Scale) was 65.0 (0.0-95.0). Concerning the EQ-5D profile, 12.2% of patients reported moderate problems with "mobility" and 27.6% with "self-care" (nobody reported severe problems), 53.0% moderate/severe problems with "usual activities", 95.1% moderate/severe levels of "pain/discomfort", 65.9% moderate/ severe levels of "anxiety/depression". After 2 months from enrolment, the SCORAD decreased significantly (Wilcoxon-SignedRanks test, p < 0.0001) and patients reported higher levels of wellbeing (Wilcoxon-Signed-Ranks test for DLQI or EQ-VAS, p < 0.0001). Also the EQ-5D profile significally got better for "usual activities" (McNemar test: p < 0.001), "pain/discomfort" and "anxiety/depression" (McNemar test: p < 0.0001). CON-CLUSIONS: This is the first study evaluating the QoL consequences of AD in Italy. Adults with AD have impaired levels of HRQoL, worsening during the relapse period. The adoption of HRQoL instruments can help physicians and decision-makers in the adoption of more effective and efficient health care technologies.
PSK10 OVERCOMING DIFFERENTIAL ITEM FUNCTIONING ASSOCIATED WITH MEASURING PATIENT REPORTED OUTCOMES IN MULTINATIONAL CLINICAL TRIALS
McKenna SP, Meads DM, Doward LC Galen Research, Manchester, UK OBJECTIVES: Little attention has been paid to determining whether different language versions of the same patient-reported outcome (PRO) measure are equivalent and if their use introduces bias into multinational studies in the form of differential item functioning (DIF). The study was designed to see whether it is possible to overcome such DIF in the development of PRO measures. METHODS: Data collected with a draft PRO-the 12-item Quality of Life Index for Children with Atopic Dermatitis (QoLICAD)-from France, Germany, Italy, The Netherlands and USA were analysed. Rasch analyses were applied to the data from each country to determine item fit and DIF by culture. Where some but not all items display DIF, it is possible to treat them as a different item in each country. This procedure is referred to as "splitting" items. The analysis was then re-run on the new item sets. RESULTS: Data were available on 691 (52.4%M; mean age 4.4 years) children in the 5 countries. Rasch analyses applied to the data indicated that, following the removal of misfitting items, there was considerable DIF by country. A European and separate US QoLICAD were derived. Four items were deleted and four were split to create a 20-item European scale that fitted the Rasch model (Chi2 p < 0.002 after bonferroni correction). Five items were deleted before the US scale fitted the Rasch model (Chi2 p < 0.004 after bonferonni correction). The European and US data were linked by six common items allowing pooling of data from an international study. CON-CLUSIONS: Language adaptations should be conceptually equivalent to the original. However, DIF by culture may remain. If data are to be pooled such DIF needs to be assessed and accounted for. The method illustrated is a suitable way of achieving this but requires further testing in a clinical trial setting. The preferences of patients and their care-givers should be considered in the development of treatment strategies. The aim is to establish care-givers' preferences and their willingness-to-pay (WTP) on different Atopic Dermatitis (AD) treatment options. METHODS: The CODA study was a naturalistic, multicentre, longitudinal ambispective (retro-prospective), prevalence based Cost-of-Illness study. Data on patients with moderate or severe AD enrolled during flare-up were collected. A discrete-choice-experiment (DCE) was applied to care-givers of the enrolled children. enrolled patients. The enrolled subjects had to choose between two different scenarios in 16 pair-wise comparisons. The following attributes were considered to be important after interviewing 20 care-givers and 6 physicians: distribution mode (local-pharmacy vs. hospital-pharmacy), the delay of The rapeutic-response (4 hours vs. 24 hours vs. 48 hours), duration of therapeutic-response (1 week vs. 4 weeks vs. 8 weeks), long-term side effects (possible vs. no), local side effects (possible vs. no). In order to obtain the WTP we added cost of treatment out-of-pocket (€0 vs. €50 vs. €100/month). RESULTS: The caregivers (98% parents) of 79 valid children filled in the
PSK11 CARE GIVERS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT
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